- Home
- BAH vs ICLR Comparison
BAH vs ICLR Comparison
Compare BAH & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BAH | ICLR |
|---|---|---|
| Founded | 1914 | 1990 |
| Country | United States | Ireland |
| Employees | 31500 | N/A |
| Industry | Professional Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.3B |
| IPO Year | 2010 | 2001 |
Fundamental Metrics
Financial Performance| Metric | BAH | ICLR |
|---|---|---|
| Price | $60.78 | $169.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 13 |
| Target Price | $97.00 | ★ $178.62 |
| AVG Volume (30 Days) | ★ 2.1M | 1.2M |
| Earning Date | 05-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.90 | N/A |
| Revenue | ★ $11,217,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.14 | N/A |
| P/E Ratio | ★ $8.66 | $12.91 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $59.63 | $66.57 |
| 52 Week High | $120.05 | $211.00 |
Technical Indicators
Market Signals| Indicator | BAH | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 24.54 | 73.24 |
| Support Level | N/A | $156.94 |
| Resistance Level | $82.42 | $192.14 |
| Average True Range (ATR) | 2.73 | 7.51 |
| MACD | -1.77 | 1.11 |
| Stochastic Oscillator | 6.62 | 96.60 |
Price Performance
Historical ComparisonAbout BAH Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.
About ICLR ICON plc
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.